Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders ; volume:16 ; number:1 ; day:20 ; month:3 ; year:2021 ; pages:1-3 ; date:12.2021
Orphanet journal of rare diseases ; 16, Heft 1 (20.3.2021), 1-3, 12.2021
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-021-01687-7
- URN
-
urn:nbn:de:101:1-2021050615532952391589
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lochmüller, Hanns
- Ramirez, Antonio Nino
- Kakkis, Emil
- SpringerLink (Online service)
Ähnliche Objekte (12)
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Clinical outcomes in Duchenne Muscular Dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome
Recommendations for improving the quality of rare disease registries
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Clinical outcomes in Duchenne Muscular Dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome
Recommendations for improving the quality of rare disease registries
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Correction to: Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome
Correction to: A guide to writing systematic reviews of rare disease treatments to generate FAIRcompliant datasets: building a Treatabolome
Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy
The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations
The medical action ontology: a tool for annotating and analyzing treatments and clinical management of human disease
The TREAT‐NMD DMD global database: analysis of more than 7,000 duchenne muscular dystrophy mutations
Clinical outcomes in Duchenne Muscular Dystrophy: a study of 5345 patients from the TREAT-NMD DMD global database
Biallelic PTPMT1 variants disrupt cardiolipin metabolism and lead to a neurodevelopmental syndrome